Novo Nordisk Raises Outlook On GLP-1 Sales
Novo Nordisk increases outlook due to higher GLP-1 sales
Story updates
04:34:35 PM UTC
SquawkNews
NOVO NORDISK OUTLOOK FY ADJUSTED EBIT GROWTH -6 TO 0% || OUTLOOK FY ADJUSTED REVENUE GROWTH -6 TO 0% || Q2 2026 ADJ SALES UP 7% AT CER; ADJ OPERATING PROFIT UP 11% AT CER
04:36:43 PM UTC
SquawkNews
NOVO NORDISK: IMPROVED OUTLOOK IS DRIVEN BY INCREASED EXPECTATIONS FOR GLP-1 PRODUCT SALES || Q2 2026 ADJ SALES DKK 78.49 BLN; ADJ OPERATING PROFIT DKK 33.39 BLN || DKK 6.3 BLN NON-RECURRING, NON-CASH IMPAIRMENT CHARGES IN Q2 2026 RELATED TO INTANGIBLE PIPELINE ASSETS
04:50:53 PM UTC
SquawkNews
more on NVO Novo Nordisk Q2 Earnings: Cuts Full-Year Outlook Again ⠀ • Q2 adjusted sales were DKK 78.49 billion and adjusted operating profit was DKK 33.39 billion, with sales up 7% and operating profit up 11% at constant exchange rates. • Novo Nordisk now expects full-year adjusted sales growth of -6% to 0% at constant exchange rates, versus market expectations of -5.9%. • The company also guides for full-year adjusted operating profit growth of -6% to 0% at constant exchange rates.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.